Bridgeway Capital Management, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.28 - $0.93 $28,000 - $93,000	-100,000 Reduced 48.38%	106,700 $32,000
Q2 2023 Aug 14, 2023	BUY	$0.55 - $1.26 $55,000 - $126,000	100,000 Added 93.72%	206,700 $144,000
Q1 2023 May 15, 2023	BUY	$0.89 - $2.52 $94,963 - $268,884	106,700 New	106,700 $96,000
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $299,400 - $537,600	-60,000 Reduced 63.9%	33,900 $214,000
Q1 2022 May 16, 2022	SELL	$3.84 - $9.74 $134,400 - $340,900	-35,000 Reduced 27.15%	93,900 $779,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $9.23 $1.01 Million - $1.19 Million	128,900 New	128,900 $1.1 Million
Q1 2020 May 15, 2020	SELL	$4.91 - $14.7 $459,085 - $1.37 Million	-93,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$8.1 - $16.0 $190,350 - $376,000	23,500 Added 33.57%	93,500 $921,000
Q3 2017 Nov 14, 2017	BUY	$7.7 - $11.55 $539,000 - $808,500	70,000	70,000 $770,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.